Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By



This article was originally published in The Tan Sheet

Executive Summary

Nasdaq sends Cyanotech delisting warning letter June 18 for "failure to comply with the $1 minimum bid price." Company has until Sept. 16 to regain compliance. Also, FDA acknowledges receipt of May 28 joint letter from firm and Earthrise Nutritionals asking agency to stop evaluating ingredient spirulina as being GRAS for use in bars, powdered nutritional drink mixes while firms "clarify and prepare additional information for a new notice." Cyanotech and Earthrise jointly had submitted a GRAS petition for spirulina microalgae March 21 (1"The Tan Sheet" April 22, 2002, In Brief)...

You may also be interested in...

Banner laxative petition denied

Data presented by Banner Pharmacaps fails to show docusate calcium can be interchanged with docusate sodium, FDA says in a Nov. 17 letter. The firm asked in a 2002 petition that the two ingredients be considered interchangeable in OTC laxative drug product monograph combinations. (1"The Tan Sheet" June 24, 2002, In Brief). The agency says data are needed showing the bioavailability of docusate calcium relative to docusate sodium "is not affected when combined with sennosides A and B or sodium carboxymethylcellulose." The letter recommends firm contact the agency's OTC division before commencing new studies...

Spirulina GRAS filing

Cyanotech and Earthrise Nutritionals submit joint March 21 GRAS petition to FDA for use of Spirulina microalgae as an ingredient in bars, powdered nutritional drink mixes "at levels ranging from .5 to 3 g per serving size." Cyanotech currently markets Spirulina Pacifica dietary supplements in pure powder and tablet form...

Philips Expert Urges Device Makers: Update Quality Systems To Conform To Revised Risk Standard ISO 14971

It’s time for manufacturers to begin adopting the new 2019 version of ISO 14971, the international standard for risk management widely used by industry. But firms need to do more work than just changing the date on risk-related procedures and documents to “2019,” says Jos Van Vroonhoven, a senior manager at Philips Healthcare who was intimately involved with the standard’s redo. From conducting gap assessments to creating cross-functional teams, both Van Vroonhoven and longtime industry expert Don Powers tell Medtech Insight how firms can keep their quality systems up-to-date to conform to ISO 14971:2019.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts